Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Submit your abstract for ESMO Asia 2024, 6-8 December, Singapore! Don't miss the chance to present your research and join us in advancing oncology. Merit Travel Grants available
Amplify the impact of your work and contribute to the global fight against cancer
View the resources for this thought-provoking discussion of three recent, important publications
The MAP 2024 Scientific Co-Chairs encourage you to submit your abstract for this prestigious congress, happening from 16 to 18 October, in London, UK. Share your latest discoveries on precision oncology and translational research
Global Exposure: Present your research to an international audience of experts and innovators, enhance your profile and gain valuable feedback
Online application is now open until 27 Aug 2024
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Evidence for efficacy is based on the results from the KRYSTAL-1 study
Findings from the innovaTV 301/ENGOT-cx12/GOG-3057 study
In the Cohort B of the TACTI-003 study, the combination therapy led to clinically meaningful response rates in patients with recurrent or metastatic disease
Penile cancer is a rare genital malignancy. This ESMO Clinical Practie Guideline provides recommendations for diagnosis, staging, pathology, treatment and follow-up. It includes algorithms for the management of primary penile tumours and inguinal lymph nodes. In clinical practice, all recommendations provided need to be discussed with patients in a shared decision-making approach
Findings from the IMROZ and BENEFIT studies
It is intended for the treatment of patients with urothelial carcinoma harbouring FGFR3 alterations
The aim is to harmonise results between different laboratories and facilitate clinical decision-making for physicians
Final results of the COMBI-AD study
Evidence for efficacy is based on the results from the TRIDENT-1 study
Evidence for efficacy is based on the results from the KRYSTAL-1 study
Findings from the innovaTV 301/ENGOT-cx12/GOG-3057 study
Findings from the IMROZ and BENEFIT studies
It is intended for the treatment of patients with urothelial carcinoma harbouring FGFR3 alterations
Final results of the COMBI-AD study
Evidence for efficacy is based on the results from the TRIDENT-1 study
Findings from the MARIPOSA study
Findings from the INTUITT-NF2 study
Findings from the DREAMM-7 and DREAMM-8 studies
Treatment of gastrointestinal (GI) cancers is catching up with other areas of oncology and offering patients better prospects for survival and quality of life, but a significant uptick in early-onset cases is raising new questions about effective prevention, diagnosis and treatment
Cross-border tumour boards of cancer specialists from different European countries meeting virtually to review the management of individual patients with complex rare gynaecological cancers from across Europe resulted in new treatment recommendations and increased access to clinical trials, according to results from a six-year study that will be presented at the ESMO Gynaecological Cancers Congress 2024
The European Society for Medical Oncology is pleased to announce the ESMO Gastrointestinal Cancers Congress 2024, the scientific congress entirely dedicated to the presentation of advances and discussions around the prevention, diagnosis and management of malignancies of the gastrointestinal tract
The ESMO Gynaecological Cancers Congress 2024 will be held in Florence, Italy, between 20-22 June, hosting international experts who will present and discuss the latest developments in the biology, diagnosis and therapy of gynaecological tumours
Ahead of World No Tobacco Day 2024, European scientific, healthcare professional and other civil society organisations call for an EU Endgame on Tobacco
First global study in young women with high-risk genes and a pregnancy after breast cancer shows Assisted Reproductive Techniques (ART) are safe, with no increase in breast cancer recurrence
ESMO Breast Cancer 2024 will be held in Berlin, Germany, between 15-17 May where the latest research in breast cancer will be presented
The European Lung Cancer Congress 2024 is the annual appointment that brings together various experts in the field of thoracic oncology
The ESMO Sarcoma and Rare Cancers Congress 2024 will be held in Lugano from 14 to 16 March and will bring together world-renowned experts among researchers and practitioners, to present and discuss the latest advances in the treatment and care of sarcoma and rare cancers in general
Hundreds of trials are being delayed in Europe due to unintended consequences of the IVDR posing an existential threat to Europe’s role as a leader in global oncological research
The Impact Factor (IF) of ESMO journals has remained strong this year, according to the 2024 Journal Citation Reports published by Clarivate Analytics
ESMO has announced today the results of its Presidential elections following the closure of the voting system on Monday, 10 June 2024.
Tom Powles, Editor in Chief of ESMO’s flagship journal Annals of Oncology; Solange Peters, ESMO Past President; and Fabrice André, President Elect of the Society have been recognised as leading and influential researchers for their remarkable achievements in cancer care
Following the Ombudsman’s recent findings of maladministration regarding the Commission’s interactions with tobacco lobbyists and its subsequent decision not to bring forward the proposed Council recommendation on smoke-free environments, it is beyond belief that the Commission now appears to have removed plans to publish an evaluation – originally meant to come in 2022 - of the Tobacco Products Directive from its implementation
The European Society for Medical Oncology (ESMO) announced today that the 2024 ESMO Breast Cancer Award is conferred to Hope S. Rugo, Professor of Medicine and Winterhof Family Professor of Breast Cancer at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
The European Society for Medical Oncology (ESMO) announced today that the 2024 Heine H. Hansen Award is bestowed to Enriqueta Felip
The nomination process for the 2024 ESMO Society Awards is now open
ESMO is pleased to announce the newly appointed Committee and Working Group Chairs who started their mandates in January 2024
In the Cohort B of the TACTI-003 study, the combination therapy led to clinically meaningful response rates in patients with recurrent or metastatic disease
The aim is to harmonise results between different laboratories and facilitate clinical decision-making for physicians
In an ESMO-SIOPE survey, only 10% of respondents report they received adequate education in medical school about how to tailor cancer care to this population
Benefits reported for the combination of ipilimumab and nivolumab further expand alternative therapeutic options for patients with unresected advanced disease
Novel agents, a rethinking of accepted treatment concepts and new roles for older treatment modalities are now driving liver cancer management
Data from clinical trials show the value of liquid biopsy in treatment decision-making and prognostication
Lessons learned about the importance of the gut microbiome composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care
In the TRANSMET trial, a 5-year overall survival benefit was observed in a highly selected patient population
Final results of the KEYNOTE-585 study indicate that the current treatment standard for resectable G/GEJ should remain unchanged
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Germany
Switzerland
Spain
Portugal
Portugal
Republic of Singapore
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Members: the main session of the ESMO Examination 2023 will be held on Saturday 21 October during the ESMO Congress 2023.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
